Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Stopped early · Phase 2

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

In brief

RATIONALE: There is emerging data to suggest that the optimal use of angiogenesis inhibitors may be in combination with chemotherapy. The optimal use of atrasentan may be in combination with chemotherapy in women with relapsed and refractory ovarian cancer,fallopian tube cancer, and peritoneal serous papillary adenocarcinoma. Due to its manageable toxicity profile, ease of administration, and activity in both platinum sensitive as well as platinum-resistant patients, Doxil has become the 2nd-line treatment of choice for women with advanced stage ovarian cancer that has progressed following 1st-line platinum/taxane therapy. PURPOSE: To determine if a treatment combination of atrasentan + Doxil is an effective 2nd line treatment in patients with recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer.

Key facts

Study ID

NCT00653328

Run by

Vanderbilt-Ingram Cancer Center

People needed

15

Starts

2003-05-01

Expected to finish

2009-03-01

Last updated by the study team

2012-05-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed adenocarcinoma arising from the ovary, fallopian tubes, or peritoneum (i.e., peritoneal serous papillary adenocarcinoma)
• Received prior treatment with either cisplatin or carboplatin in combination with paclitaxel or docetaxel as first-line chemotherapy
• Radiographic evidence of progressive disease and/or a doubling of CA-125 levels ≥ 70 IU/mL following first-line chemotherapy
• Measurable disease as defined by RECIST criteria
• No CNS metastases
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/μL
• Hemoglobin ≥ 9.5 g/dL
• Platelets > 100,000/μL
• Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 times ULN
• AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if liver metastases are present)
• LVEF ≥ 50% by MUGA
• Not pregnant or nursing
• Negative pregnancy test
• Surgically sterile or must use effective contraception
• No known HIV positivity or AIDS
• No uncontrolled heart disease, diabetes, or other medical condition that would place the patient at unacceptably high risk for toxicity
• No New York Heart Association class I-IV heart failure

You may not qualify if…

• Not specified
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from all prior toxicities to ≤ grade 1 by NCI-CTC Version 2 criteria
• No other prior systemic therapies for this cancer except cisplatin or carboplatin in combination with paclitaxel or docetaxel as first-line chemotherapy
• More than 4 weeks since prior chemotherapy
• No concurrent anticancer therapy

Where it is running

• Central Georgia Hematology Oncology Associates, P.C. — Macon, Georgia, United States
• Kentuckiana Cancer Institute — Louisville, Kentucky, United States
• The Jones Clinic — Germantown, Tennessee, United States
• Jackson-Madison County Hospital — Jackson, Tennessee, United States
• St. Thomas Health Services — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.